You are here: Industry Insights > APT

News List

Biomanufacturers are facing persistent malware attacks, says cybersecurity group Pharmaceutical-Technology
November 26, 2021
The Bioeconomy Information Sharing and Analysis Center (BIO-ISAC) has released an advisory following an investigation into an advanced persistent threat (APT) attack targeting biomanufacturing facilities.
FDA clears expanded access IND for APT’s PhageBank therapy for Covid-19-related bacterial infections pharmaceutical-business-review
November 23, 2020
Adaptive Phage Therapeutics (APT) announced clearance by the U.S. Food and Drug Administration (FDA) of the company’s Expanded Access IND for PhageBank treatment for pneumonia or bacteremia/septicemia due to Acinetobacter baumannii, Pseudomonas ...
FDA clears first clinical study for a polymicrobial phage library-based treatment for antibiotic-resistant infections pharmaceutical-business-review
March 17, 2020
Adaptive Phage Therapeutics (APT) said that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the clinical development of PhageBank.